A real-world study on the efficacy and safety analysis of paclitaxel liposome in advanced breast cancer.
10.3760/cma.j.cn112152-20220129-00069
- VernacularTitle:紫杉醇脂质体在晚期乳腺癌中应用的真实世界研究
- Author:
Chun Xiao SUN
1
;
Shu Sen WANG
2
;
Jian Bin LI
3
;
Yong Sheng WANG
4
;
Qu Chang OUYANG
5
;
Jin YANG
6
;
Hai Bo WANG
7
;
Xiao Jia WANG
8
;
Wen Yan CHEN
9
;
Peng YUAN
10
;
Min YAN
11
;
Ze Fei JIANG
3
;
Yong Mei YIN
1
Author Information
1. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
2. Department of Medicial Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510062, China.
3. Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
4. Department of Breast Surgery, Shandong Cancer Hospital, Jinan 250117, China.
5. Department of Breast Medical Oncology, Hunan Cancer Hospital, Changsha 410031, China.
6. Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
7. Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qingdao University, Qingdao 266003, China.
8. Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310005, China.
9. Department of Mediacl Oncology, The Third Hospital of Nanchang, Nanchang 330008, China.
10. Department of VIP Medical, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
11. Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou 450003, China.
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Efficacy;
Paclitaxel liposome;
Real-world study;
Safety
- MeSH:
Humans;
Female;
Breast Neoplasms/chemically induced*;
Paclitaxel/adverse effects*;
Liposomes/therapeutic use*;
Retrospective Studies;
Treatment Outcome;
Trastuzumab/therapeutic use*;
Capecitabine/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*
- From:
Chinese Journal of Oncology
2023;45(1):88-94
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the application and efficacy of paclitaxel liposome in the treatment of advanced breast cancer among Chinese population in the real world. Methods: The clinical characteristics of patients with advanced breast cancer who received paclitaxel liposome as salvage treatment from January 1, 2016 to August 31, 2019 in 11 hospitals were collected and retrospectively analyzed. The primary outcome was progression free survival (PFS), and the secondary outcome included objective response rate (ORR) and safety. The survival curve was drawn by Kaplan-Meier analysis and the Cox regression model were used for the multivariate analysis. Results: Among 647 patients with advanced breast cancer who received paclitaxel liposome, the first-line treatment accounted for 43.3% (280/647), the second-line treatment accounted for 27.7% (179/647), and the third-line and above treatment accounted for 29.1% (188/647). The median dose of first-line and second-line treatment was 260 mg per cycle, and 240 mg in third line and above treatment. The median period of paclitaxel liposome alone and combined chemotherapy or targeted therapy is 4 cycles and 6 cycles, respectively. In the whole group, 167 patients (25.8%) were treated with paclitaxel liposome combined with capecitabine±trastuzumab (TX±H), 123 patients (19.0%) were treated with paclitaxel liposome alone (T), and 119 patients (18.4%) were treated with paclitaxel liposome combined with platinum ± trastuzumab (TP±H), 108 patients (16.7%) were treated with paclitaxel liposome combined with trastuzumab ± pertuzumab (TH±P). The median PFS of first-line and second-line patients (5.5 and 5.5 months, respectively) were longer than that of patients treated with third line and above (4.9 months, P<0.05); The ORR of the first line, second line, third line and above patients were 46.7%, 36.8% and 28.2%, respectively. Multivariate analysis showed that event-free survival (EFS) and the number of treatment lines were independent prognostic factors for PFS. The common adverse events were myelosuppression, gastrointestinal reactions, hand foot syndrome and abnormal liver function. Conclusion: Paclitaxel liposomes is widely used and has promising efficacy in multi-subtype advanced breast cancer.
